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Primary eﬀusion lymphoma (PEL) is a rare extranodal lymphoma that typically presents in a body cavity in the absence of
a detectable tumor mass and that occurs predominantly in immunosuppressed individuals. e neoplastic lymphoid cells are
frequently infected with human herpes virus 8 (HHV8), also known as Kaposi sarcoma herpes virus (KSHV). We describe two
HIV-negative patients who presented with primary eﬀusion lymphoma of B-cell lineage involving the pleural cavity, but whose
tumor cells lacked infection by HHV8. We review the English language literature of HHV8-negative PEL of B-cell lineage and
comparetheselymphomastoHHV8-associatedPELwithregardtoclinicalandpathologicalcharacteristics,therapy,andoutcome.
1. Introduction
Primary eﬀusion lymphoma (PEL) is a rare extranodal
lymphoma of large B cells with characteristic clinicopatho-
logic features including: initial presentation as a body cavity
lymphomatous eﬀusion in the absence of a detectable tumor
mass; occurrence mostly in human immunode�ciency virus
(HIV)-positive individuals; and expression of antigens asso-
ciatedwithalatestageofB-celldiﬀerentiation,suchasCD138
and MUM1/IRF4, without pan-B-cell antigen expression [1].
Human herpes virus-8 (HHV8), also known as Kaposi’s
sarcoma herpes virus (KSHV), is strongly causally related to
PEL and its presence has been incorporated as a diagnostic
criterion for PEL [2].
Diﬀuse large B-cell lymphoma (DLBCL) constitutes
approximately 30–40% of all non-Hodgkin’s lymphoma
(NHL) and typically presents with a rapidly enlarging symp-
tomatic mass, usually due to nodal enlargement. Extranodal
disease with involvement of tissue other than lymph node,
spleen, Waldeyer’s ring or thymus is quite common in
DLBCL, as is secondary involvement of a body cavity by
DLBCL [3]. However, primary presentation of DLBCL as a
body cavity lymphomatous eﬀusion without any detectable
solid mass, similar to HHV8-associated PEL, is extremely
rare. Reports of such cases of HHV8-negative PEL of B-
cell lineage are limited to isolated case reports and small
series. We report two additional cases of this aggressive
extranodal lymphoma that presented as a solitary pleural
eﬀusionwithoutothersitesofdiseaseatthetimeofdiagnosis.
In addition, we perform a comprehensive literature review
of similar cases with the aim of further characterizing this
unusual lymphoma subtype.
Case 1. An 87-year-old HIV-negative Portuguese female
with a past medical history of heart failure with preserved
ejectionfraction(EF = 60%),hypertension,atrial�brillation,
dyslipidemia, and degenerative joint disease was admitted
with progressive shortness of breath of two weeks’ duration.
Complete blood count on admission revealed WBC count
of 9600/𝜇𝜇L, hemoglobin of 13.7g/dL, hematocrit of 42.0%,2 Case Reports in Oncological Medicine
(a) (b) (c)
(d) (e) (f)
F 1: Cytological analysis revealed large atypical lymphoid cells with irregular nuclei, prominent nucleoli and basophilic vacuolated
cytoplasm ((a), May-Grünwald-Giemsa; (b), Papanicolaou). By immunohistochemistry of a corresponding cell block specimen, the large
cells were strongly positive for CD45 (c), CD20 (d), and CD79a (e), and were negative for CD138 (f), indicative of a mature B-cell
immunophenotype.
and platelet count of 160,000/𝜇𝜇L. Serum total protein and
LDH were 6.4g/dL and 184IU, respectively. e chest X-ray
showed an enlarged cardiac silhouette with bilateral pleural
eﬀusions. oracocentesis revealed the pleural �uid to be
exudative with glucose of 3mg/dL, protein of 3.5g/dL, LDH
of 1341U/L and 9600 nucleated cells/𝜇𝜇L, of which 5100
were normal-appearing white blood cells (6% neutrophils,
91% lymphocytes, 3% monocytes) and 4500 were malignant-
appearing cells.
Cytocentrifuge preparation showed the malignant cells
to be large lymphoid cells with irregular nuclei and deeply
basophilic cytoplasm with prominent vacuoles (Figures 1(a)
and 1(b)). Flow cytometry of the pleural �uid showed
that the large cells were positive for CD45, CD19, CD20,
CD22, CD79a, CD38, HLA-DR, and surface IgM, with
aberrant expression of the T-cell antigen, CD8, and the
myeloid antigen, CD13. ey were negative for surface
and cytoplasmic light chains, MPO, TdT and other T-cell
antigens (CD2, CD3, CD4, CD7). Immunoperoxidase stains
showed that neoplastic cells were positive for CD45 (Figure
1(c)), CD20 (Figure 1(d)), CD79a (Figure 1(e)), bcl-2, bcl-6
(>50%), Ki-67 (>90%), epithelial membrane antigen (<50%)
and negative for CD10, CD30 and CD138 (Figure 1(f)).
Immunohistochemical staining for HHV8 latency associated
nuclear antigen (LANA)-1 and in-situ hybridization (ISH)
for Epstein-Barr virus (EBV) were negative. e patient was
diagnosedwithDLBCL.Furtherstagingtoexcludeaprimary
extra-cavitary site of involvement was performed; however,
no mass, organomegaly or lymphadenopathy was detected
on computed tomography (CT) scans of the chest, abdomen
or pelvis. Ultimately, it was felt that a diagnosis of HHV8-
negative PEL was most appropriate. e patient was treated
only with talc pleurodesis as she declined chemotherapy and
radiotherapy. She is alive approximately 24 months aer
the procedure and a total of 29 months aer her initial
presentation of bilateral pleural eﬀusions.
Case 2. An 82-year-old HIV-negative Caucasian female with
a past medical history of hypertension, sick sinus syndrome,
abdominal aortic aneurysm and chronic obstructive pul-
monarydiseasewasadmittedwithdyspnea.Tenyearsearlier,
she was diagnosed with non-small cell lung cancer that was
treatedwithconcurrentneoadjuvantchemotherapyandradi-
ation followed by lobectomy. She had no interval clinical or
imaging evidence of recurrence of her thoracic malignancy.
Chest radiograph during the admission showed a right-sided
pleural eﬀusion. oracocentesis revealed malignant cells in
the pleural �uid that were large lymphoid cells with irregular
nuclearcontours,basophiliccytoplasmandmultiplenucleoli
(Figures2(a)and2(b)).Immunohistochemicalstainsshowed
the neoplastic cells to be positive for CD20 (Figure 2(c)),
PAX5/BSAP, bcl-6, MUM1/IRF4 (subset) and kappa light
chain (Figure 2(d)), weakly positive for bcl-2, and negative
for CD5, CD10, CD15, CD30, CD138, cyclin D1, lambda
light chain (Figure 2(e)) and HHV8 LANA-1. ISH for EBV-
encoded RNA (EBER) was negative. Immunoglobulin heavy
chain (IGH@) gene rearrangement studies showed a clonalCase Reports in Oncological Medicine 3
(a) (b) (c)
(d) (e) (f)
F 2: Examination of the initial thoracentesis �uid demonstrated scattered large atypical lymphoid cells with multilobated nuclei,
vesicular chromatin and multiple prominent nucleoli (arrows), in a background of benign mesothelial cells, histiocytes, small lymphocytes
andneutrophils((a),le,May-Grünwald-Giemsa,andright,hematoxylinandeosin).ecorrespondingcellblockspecimenshowedsimilar
�ndings (hematoxylin and eosin). Immunohistochemical stains showed the scattered large cells to be positive for CD20 (c) and kappa light
chain-restricted (d), with few lambda-positive cells in the background (e). A repeat thoracentesis specimen taken 1 month later showed no
evidence of malignancy, with only benign mesothelial cells (arrow) and hematopoietic elements (Wright-Giemsa).
pattern [4]. F-Fluorodeoxyglucose (FDG) positron emission
tomography (PET)/CT whole body scan for staging did not
demonstrate additional sites of disease. e expression of
mature B-cell markers and absence of HHV8, EBV, CD30
and CD138 expression excluded the diagnosis of HHV8-
associated PEL and the patient was given the diagnosis of
HHV8-negative PEL.
e patient became symptomatic with dyspnea a month
later and chest X-ray showed recurrent pleural eﬀusion.
oracocentesis was repeated and examination of the pleu-
ral �uid by cytology and �ow cytometry revealed only
reactive mesothelial cells and histiocytes, without evidence
of malignant-appearing cells (Figure 2(f)). No clonal B-
cell population was detected by concurrent �ow cytometry.
Spontaneous regression of lymphoma was re-con�rmed with
repeat thoracocentesis a week later yielding no malignant
cells. However, follow-up FDG PET/CT whole body scans
done 4 months later showed a new FDG-avid pleural-based
smallnoduleandvariousnodularitiesintheomentum.Tissue
biopsy of these nodules was not attempted, but they were
believed to be consistent with metastatic progression of the
lymphoma. e patient refused any chemotherapy and died
11 months aer her diagnosis of lymphoma.
2. Design and Methods
“Primary eﬀusion lymphoma” and “body cavity based lym-
phoma” were used as search terms to identify English-
languagearticlesfromPubMedpublishedinthepast15years
(January 1997 to June 2012). Primary eﬀusion lymphoma
was de�ned by the presence of malignant lymphoma cells
exclusivelyinabodycavityorcavitieswithoutanycontiguous
or non-contiguous tumor mass or lymph node enlargement
at the time of presentation. e review was restricted to
reports of primary eﬀusion lymphomas that were negative
for HHV8 and that showed expression of mature pan-B-cell
antigens. Editorials, reviews without additional cases, and
non-published abstracts were excluded.
Clinical information abstracted for each case included:
age at presentation; sex; HIV status by enzyme-linked
immunosorbent assay (ELISA) or Western blot studies;
detection of hepatitis C virus (HCV) by serologic studies
or polymerase chain reaction (PCR); detection of EBV by
PCR; site(s) of disease; therapy; and outcome. Pathological
data collected for each case included: lymphoma cell mor-
phology and immunophenotype; HHV8 LANA-1 expression
by immunohistochemistry or detection of HHV8 by PCR or
ISH; detection of EBV by EBV latent membrane protein-1
(LMP1) expression or EBER ISH; and results of IGH@ gene
rearrangement and cytogenetic studies.
3. Results
e preliminary search for reports using the above men-
tioned terms yielded 1187 articles. Aer excluding reports
of HHV8-associated PEL and cases of T-cell or null
immunophenotype, we identi�ed 34 articles describing 46
unique cases [4–37]. Our review includes these 46 cases and4 Case Reports in Oncological Medicine
T 1: Summary of clinical characteristics of 48 patients with
HHV8-negative eﬀusion lymphomas of B-cell lineage.
Characteristics Number of patients (%)
Age (n = 48)
Age > 60 10 (20.8)
Age < 60 38 (79.2)
Sex (n = 48)
Male 29 (60.4)
Female 19 (39.6)
E B Vs t a t u s( n = 47)
Positive 10 (21.3)
Negative 37 (78.7)
H C Vs t a t u s( n = 36)
Positive 8 (22.2)
Negative 28 (77.8)
Site(s) involved (n = 41)
Pleura 27 (65.9)
Peritoneum 16 (39.0)
Pericardium 15 (36.6)
Treatment (n = 48)
No chemotherapy 17 (35.42)
CHOP 11 (22.92)
CHOP + R 3 (6.25)
THP-CVP 6 (12.5)
THP-CVP + R 4 (8.3)
Other regimens 6 (12.5)
Unknown 1 (2.0)
Outcome
A t6m o n t h s( n = 45)
Dead (10/45) 22.2%
Alive (35/45) 77.8%
A t1y e a r( 𝑛𝑛 𝑛 𝑛𝑛)
Dead (14/36) 38.9%
Alive (22/36) 61.1%
Abbreviations: CHOP: cyclophosphamide, doxorubicin, vincristine, pred-
nisone; R: Rituximab; THP-CVP-pirarubicin, cyclophosphamide, vin-
cristine, prednisone; EBV: Epstein-Barr virus, HCV: hepatitis C virus.
our 2 cases for a total of 48 reported cases of HHV8-negative
PEL.
Clinical characteristics are summarized in Table 1 and
detailed clinical and pathological �ndings in each case are
listedinTable 2.e48patientshadamedianageatdiagnosis
of 74 years (range: 14–99 years) with a male-to-female ratio
of 3:2. Information regarding HIV status was available in
41 patients, and none were reported to be HIV-positive.
e association with HCV and EBV infection was found
to be 22.2% and 21.3%, respectively. For the 41 patients
with information available regarding site of disease, the
frequencies of various sites of involvement were as follows:
pleura: 65.9%, peritoneum: 39.0%, and pericardium: 36.6%.
A single case (case 48) involved the scrotum.
Most cases consisted of medium-sized to large or large-
sized cells that were occasionally described as pleomorphic.
All cases expressed one or more pan-B-cell antigens (CD19,
CD20 and/or CD79a) and several cases expressed sur-
face and/or cytoplasmic immunoglobulin, antigens typically
absent in HHV8-associated PEL [16]. e immunopheno-
type was variable with regard to germinal center (CD10, bcl-
6) and post-germinal center (MUM1/IRF4) markers, but no
case was reported to express CD138, a plasmacytic antigen
typically seen in HHV8-associated PEL. Expression of T-cell
antigens, a feature reported in occasional cases of HHV8-
associated PEL, was seen in only rare cases (two cases with
CD5 co-expression [22, 23]a n dc a s e1r e p o r t e da b o v ew i t h
CD8 co-expression). At least some cytogenetic information
(FISH and/or karyotype) was available in 26 cases. Of these,
12 cases showed a rearrangement or ampli�cation involving
MYC at8q24and13werereportedtoharboracomplexkary-
otype, although full karyotypic information was available in
only a small number of cases.
irty patients (62.5%) received chemotherapy with a
variety of regimens, including cyclophosphamide, doxoru-
bicin, vincristine, prednisolone (CHOP) in 11 patients;
CHOP with rituximab (R) in 3 patients; THP-CVP (piraru-
bicin, cyclophosphamide, vincristine, prednisolone) in 6
patients; THP-CVP + R in 4 patients; and other chemother-
apy regimens in 6 patients. Treatment was unknown in
1 patient. e remaining 17 patients (35.4%) received no
chemotherapy and were treated with �uid drainage alone or
�uid drainage and pleurodesis. e median overall survival
(OS) was 11 months. e number of patients alive at 6
months and 1 year following symptomatic presentation was
77.8% and 61.1% respectively. Patients who received no
chemotherapyhadamedianOSof8months(range:1weekto
80 months) versus 12 months (range: 18 days to 38 months)
in patients who received any kind of chemotherapy. e rate
ofdeathwithanykindofchemotherapyat6monthswas20%
a n da t1y e a rw a s3 3 %, compared to 25% and 42% without
any chemotherapy. Among the 22 patients who died of their
lymphoma, the median OS was 7 months (range: 1 week
to 80 months). e median follow-up period in 24 living
patients was approximately 14.5 months (range: 2 months to
55 months).
4. Discussion
Body cavity-based lymphomas are a heterogeneous group of
rare non-Hodgkin’s lymphomas that arise primarily in the
serous body cavities and that result in recurrent eﬀusions.
is group includes pyothorax-associated lymphoma and
PEL. Pyothorax-associated lymphoma presents as a solid
mass localized in the thoracic cavity that is contiguous
with the eﬀusion; it is EBV-associated and arises in the
setting of long-standing pyothorax resulting from iatrogenic
pneumothorax used to treat tuberculosis [38]. In contrast,
PEL is typically con�ned to a body cavity and grows in a
liquidphase,withoutanydetectablenodalorextranodalmass
elsewhere in the body. As illustrated in Figure 3, PEL can be
broadlydividedintotwocategories:HHV8-associatedPEL,a
subtype of DLBCL and a distinct category in the 2008 WHO
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Secondary lymphomatous
effusions
lymphoma
(PEL)
lymphomas
peripheral T-cell lymphoma
null/indeterminate phenotype
Mature B-cell
lymphomas
Immunoblastic, plasmablastic or
anaplastic morphology.
Absence of pan-B-cell antigens,
with expression of CD45
activation markers (CD30, CD38),
and antigens corresponding to a
(CD138, MUM1/IRF4).
Median survival: 6 months.
Pyothorax-associated
lymphoma
(PAL)
HHV-8/KSHV-negative.
Expression of pan-B-cell antigens: CD20,
CD79a, CD22, PAX5/BSAP.
Absence of CD138 expression.
Large cell morphology consistent with
DLBCL in majority of cases; few cases
with monomorphic, medium-sized cells.
Subset of cases EBV-driven, MYC-driven,
and/or HCV-associated.
Malignant lymphomatous effusions in
non-Hodgkin’s lymphoma
HHV-8/KSHV-negative effusion Primary effusion
Primary lymphomatous effusions
Median survival:
HHV-8/KSHV-positive. (i)
(ii)
(iii)
(iv)
(i)
(ii)
(iii)
(iv)
(v)
(vi)
(leukocyte common antigen),
late stage of B-cell differentiation
Rare variants (∼20%):
(∼80%)
∼1 year.
F 3: A schema of malignant lymphomatous eﬀusions in non-Hodgkin’s lymphoma highlighting the diﬀerences between HHV8-
associated PEL and HHV8-negative PEL.
Tissues [2], and HHV8-negative PEL, of which the majority
(∼80% of cases) express mature pan-B-cell antigens [39]. As
onlyrarecasesofHHV8-negativePELwithneoplasticcellsof
T-cellderivation[40–44]ornull/indeterminateimmunophe-
notype [22, 45, 46] have been reported, we restricted our
reviewtoHHV8-negativePELofB-celllineage.Ourreportof
twocasesandreviewoftheliteraturedemonstratesthatthese
neoplasmsareheterogenous,butsharecommonfeaturesthat
distinguish them from HHV8-associated PEL with regard to
pathogenesis,clinicalcharacteristics,immunophenotypeand
prognosis.
While none of the 48 patients with HHV8-negative PEL
were HIV-positive, EBV infection was seen in 21.3% of
cases, suggesting that altered immunosurveillance may play
a pathogenetic role in some cases. Among the 10 EBV-
positive cases, all patients were >50 years old, 2 patients
had idiopathic CD4+ T-cell lymphopenia and 1 patient had
a history of common variable immunode�ciency, support-
ing this hypothesis [47]. Similarly, 22.2% of patients had
underlying HCV infection. HCV has been shown to be
lymphotropicandhasbeenimplicatedasanetiologicalfactor
in lymphomagenesis for various NHL subtypes [48, 49].
Ascolietal.detectedHCVRNAintheascitic�uidofapatient
with HHV8-negative PEL and proposed that HCV may play
a causative role in these lymphomas by chronic stimulation
of B cells followed by clonal expansion [16].
In our review, a number of cases were negative for
both EBV and HCV (19/48; 39.6%), suggesting that other
etiologies also play a role in lymphomagenesis. Among cases
with available cytogenetic information, 50% (12/26) har-
bored ampli�cation or rearrangement of the MYC oncogene,
a likely driver of neoplasia in these cases. In terms of B-
cell NHL subclassi�cation, most MYC-rearranged cases had
large cell morphology or a complex karyotype, consistent
with DLBCL [14, 19, 22, 23, 26, 31, 50] Two cases (cases 17
and 18) reportedly had monomorphic medium-sized cells,
a germinal center immunophenotype (expression of CD10),
andarelativelysimplebackgroundkaryotype,suggestingthat
thesecasesmayrepresentanunusualextranodalpresentation
o fB u r k i t t ’ sl y m p h o m a[ 16, 17].
Unlike HHV8-associated PEL, HHV8-negative PEL of
B-cell lineage shares several clinical features with nodal or
extranodal DLBCL presenting with a mass lesion, and dif-
ferentiating HHV8-negative PEL from conventional DLBCL10 Case Reports in Oncological Medicine
complicated by secondary lymphomatous eﬀusion requires a
thoroughstagingevaluationtoexcludethepresenceofamass
lesionatthetimeofdiagnosis.Basedonourliteraturereview,
HHV8-negative PEL presents at an older median age (74
years) compared to that reported for HHV8-associated PEL
(44 years) and exhibits a lower male-to-female ratio, similar
to DLBCL [2, 44, 51, 52]. e overall favorable prognosis
compared to HHV8-associated PEL was underscored by a
survival rate of approximately 60% at 1 year and a median
OS of 11 months. While this compares favorably to HHV8-
associated PEL with a reported median OS of 4–6 months
[2, 44], the range was quite wide (1 week to 80 months).
is heterogeneity in clinical behavior is further highlighted
by our �nding of a small number of patients who presented
withinvolvementlimitedtoasinglebodycavitysite,butwho
developed mass lesions outside of the body cavity at the time
ofdiseaseprogression,similartoourcase 2[32]. At the other
extreme, our case 1 showed regression of the malignancy
aer pleurodesis and drainage of the pleural �uid without
any chemotherapy, and in our literature review we identi�ed
7 other patients in whom the lymphoma similarly regressed
following drainage of the eﬀusion [5–7, 12, 18, 23].
 e r ei sn oc l e a rc o n s e n s u so nt h ea p p r o p r i a t et r e a t -
ment of HHV8-negative PEL due to the limited number
of cases reported. Our �ndings suggest that chemotherapy
bene�ts most patients, as those treated with any type of
chemotherapy overall had a lower rate of death compared
to patients who received no chemotherapy. Remarkably, the
addition of rituximab to chemotherapy regimens induced
remission in all 8 patients, 7 of whom were alive at the
time of last follow-up [4, 8, 12, 13, 29, 31, 32]. e single
patient who died following a rituximab-containing regimen
died prematurely of a cause unrelated to lymphoma [8].
erefore, treatment with drainage of the eﬀusion followed
by chemoimmunotherapy with rituximab and CHOP, partic-
ularly in CD20-positive cases, appears to oﬀer the possibility
of prolonged survival in a subset of patients. Further study
of rare patients who undergo spontaneous regression of their
lymphoma following drainage alone may help to identify
clinical or pathological features that predict for a good
outcome following only minimal therapy.
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